ערך בספרים למניה: ImmuCell (ICCC)

ImmuCell Corporation is managed by experienced veterinary biotech experts who effectively protect intellectual capital. The GURU.Markets platform features a net book value per share chart, where 3.47 indicates the value of this parameter. Localizing production in the US ensures geopolitical stability, although the company's revenues remain dependent on market price cycles for dairy and meat products.

For ImmuCell Corporation (ICCC), which dominates the cattle intestinal infection antibody niche thanks to First Defense patent protection, the historical book value per share serves as an indicator of material stability. This metric is calculated as the ratio of equity minus all liabilities to the number of shares, reflecting net assets and confirming the fundamental reliability of the business over the long term.